Vaso Corporation (OTCQX: VASO)
Up 64% From Entry, First Operational Data Lands
To read our full disclaimer, click here.
In November, we published a thesis on a profitable healthcare company trading at 71% of cash per share.
In February, with the stock up 30%, we revisited after two key catalysts - a divestiture and a GE HealthCare contract extension - landed in rapid succession.
The stock is now up roughly 64% from our entry point.
Q1 2026 earnings, released May 15th, are the first operational data point under the evolving leadership structure. The thesis has played out as expected. But the easy part in my opinion is over.
Here’s what the numbers said, what they mean, and where the thesis stands today.
Read to the end for a discount…
Where We Started, Where We Are
A quick reset before the numbers, because context matters here:
November 2025: $0.14 stock price, $24M market cap, $35M cash → trading at 71% of cash
February 2026: $0.18 stock price, $31.67M market cap → trading at 91% of cash
May 2026 (today): $0.23 stock price, $40M market cap, $38.5M cash → trading at ~104% of cash
The structural mispricing we identified is essentially closed. The stock now trades at roughly its cash value, which means the easy arbitrage - buying a profitable, operating business for less than the bank account - is gone.
What’s left is the operating business itself.
So Q1 matters more than any quarter we’ve covered so far.
It’s the first chance to see whether the operational thesis - that management can turn a record backlog into actual earnings - is real.
What Q1 Actually Showed
The headline number looks soft: revenue of $19.4 million, down 0.5% year-over-year.
That’s misleading. Once you back out the healthcare IT reseller VASO divested in November, the same comparison shows revenue up 4.8%, and gross profit up 5.8%.
That’s the cleaner read.
Three things stood out underneath the headline:
The GE segment is delivering exactly as the contract extension implied. Professional sales services revenue was up 6.1% year-over-year, driven by higher imaging product deliveries from GE HealthCare and a higher blended commission rate. This is the segment that was contractually secured through 2030 in December. The first full quarter under the extended agreement confirms the relationship is producing - not just preserved.
Deferred revenue grew to a record $39.5 million, up 11.6% year-over-year. This is the metric that matters most for the long-term thesis. Deferred revenue is cash collected for services not yet delivered - it represents future earnings already in the bank. An 11.6% increase against a roughly flat revenue line means the booking machine is accelerating faster than the conversion machine. That’s both the opportunity and the bottleneck we flagged in the original post.
Net loss narrowed to $887 thousand from $1.1 million. Modest, but moving in the right direction. Adjusted EBITDA also improved slightly, from negative $1.12M to negative $1.07M. The post-divestiture business is leaner, and the early signs suggest the trim is showing up in the P&L. Q1 is seasonally the weakest quarter for VASO - management explicitly reminded investors that they’ve historically been more profitable in the later quarters of the year.
The Cash Burn Looks Worse Than It Is
The line item that will spook a casual reader: $12.6 million in cash used in operating activities, against $566 thousand in the year-ago quarter.
Management’s explanation: timing.
Payments expected in March arrived in April, distorting the quarter-end snapshot. That’s consistent with the deferred revenue growth, and the May 8 cash balance of $38.5M tells you the cash position remains healthy.
Cash per share is still roughly $0.22 against a $0.23 stock price.
I take the timing explanation at face value for now, but it’s the kind of thing that becomes a problem if it repeats. Q2 will be the tell. If operating cash flow returns to near breakeven or better, this was noise.
If it doesn’t, the working capital story needs a harder look.
The Real Concern: SG&A
The one number I’m watching closely is SG&A. It rose 2.6% to $12.7 million, despite the divestiture of an entire subsidiary that should have meaningfully reduced overhead.
Management’s breakdown: higher personnel and travel costs, plus higher consulting and accounting expenses, partially offset by savings from the IT divestiture.
Two ways to read that.
The optimistic read is that VASO is investing ahead of expected growth - David Mueller building out infrastructure, the team gearing up to convert the growing deferred revenue base.
The pessimistic read is that cost discipline is loose, and the divestiture savings are being absorbed by overhead growth before they ever reach the bottom line.
You don’t get a verdict on this from one quarter.
But it’s the number I’ll be triangulating against revenue and gross profit growth for the rest of 2026.
Updated Risk Profile
Where the original risks stand after Q1:
GE Partnership Deterioration - Still eliminated through 2030. Q1 confirms the relationship is producing, with the segment growing 6.1%.
Operational Improvements Don’t Materialize - Early but encouraging. Deferred revenue up 11.6%. Core revenue up 4.8% ex-divestiture. Net loss narrowing. The conversion of bookings to revenue is still the central question, and the answer won’t be clear until at least Q3.
Macro Headwinds - Slightly elevated. Management explicitly cited “growing uncertainties in the general business environment” and called out US tariff policy as a risk factor in the forward-looking statements. The 87% recurring revenue base in the IT segment remains the defensive anchor.
Continued Illiquidity - Still a $40M market cap on OTCQX. Anyone sizing a position needs to size it for the door.
New risk: The valuation cushion is gone. When we first wrote about VASO, you were paying 71 cents for a dollar of cash, plus the operating business for free. At $0.23, you’re paying for both. That changes the risk-reward materially. The thesis no longer has the “cash is a floor” safety net it had in November.
Where I Stand
Six months ago, VASO was a profitable company trading below cash with two specific catalysts and a partnership question mark.
Today, the partnership is secured through 2030. The weakest subsidiary is gone. Core revenue is growing. Deferred revenue is at a record. The net loss is narrowing. Management has done what it said it would do, and the stock has responded.
What’s left is a different kind of bet. The structural mispricing is closed. From here, VASO is a small-cap operating turnaround that has to keep proving itself quarter by quarter. The deferred revenue base says the demand is there. SG&A discipline and the Q2 cash flow print will say whether management can convert it.
The next decision point is Q2 earnings - specifically whether operating cash flow normalizes and whether SG&A growth slows. If both happen against another quarter of deferred revenue growth, the thesis transitions from “mispricing closing” to “quality compounder at fair value,” and the position works for a longer hold.
If Q2 looks like Q1 on cash and SG&A, the asymmetry has tightened enough that taking the gain is the right move for me.
Either way, the original thesis worked. Now we find out what kind of company VASO actually is.
One Discounted Annual Subscription
This post is free. The original VASO thesis wasn’t - paid subscribers got it on November 18 at $0.14, before the 64% move you just read about.
The next idea is already in the pipeline. If you want it when it comes out, I’m putting out one discounted annual subscription code here:
It’s 25% off, and it goes to whoever claims it first through the link above.
Thanks for reading,
Nico
Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of The Clinical Edge. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.